Best of the Blog: IN VIVO, May 2008
Executive Summary
"Best of the Blog" is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In May: Cordaptive and Claratin/Singluair feel the weight of an FDA not-approvable letter.
You may also be interested in...
Merck's Cordaptive: Just Another Cholesterol Combo, or More?
At first glance, Merck's Cordaptive is yet another combination drug for cholesterol. But by unlocking the significant medical benefits of niacin, the treatment may represent an important advance. Cordaptive contains an anti-flushing agent which reduces the key side-effect preventing wider niacin use.
Genzyme/Isis: Has ENHANCE Dulled Mipomersen's Prospects?
In early January, Genzyme nabbed one of the highest-value specialist cholesterol-busting drugs around: Phase III mipomersen, from Isis Pharmaceuticals. But given the ENHANCE-triggered questions around the value of ever-lower LDL, it's reasonable to ask whether mipomersen has a somewhat less rosy prospect in the few weeks since the deal was signed.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.